Email
Print
Prescription Antiacne Drugs Market - Forecast(2024 - 2030)
Prescription Antiacne Drugs Market Overview
Prescription Antiacne Drugs Market Size is estimated to reach $4.3 billion by 2027 and is poised to grow at a CAGR of 5.9% over the forecast period 2022-2027. Acne vulgaris is one of the most prevalent skin disorders and is primarily brought on by alterations in the structure of the skin. About 9.4% of the global population is affected by it. There are two varieties of acne: non-inflammatory and inflammatory. The inflammatory acne heals slowly and leaves a permanent mark on the skin. Drugs that are prescribed for the treatment of acne are known as acne medicines. Many prescription and over-the-counter medications fall under this category, including oral contraceptives, antibiotics, salicylic acid, benzoyl peroxide, retinoids and isotretinoin. The increasing pollution and increasing population of teenagers drive the growth of the prescription antiacne drugs industry. The increasing demand for antiacne drugs brings new products to the market. For instance, in July 2022, Glenmark Pharmaceuticals launched India's first topical Minocycline 4% Gel for the treatment of moderate to severe acne, under the brand name MINYM. Such increasing demand and new innovative products in the market drive the growth of the Prescription Antiacne Drugs Market over the forecast period 2022-2027.
Prescription Antiacne Drugs Market Report Coverage
The report: “Prescription Antiacne Drugs Market Forecast
(2022-2027)" by IndustryARC, covers an in-depth analysis of the following
segments in the Prescription Antiacne Drugs Market.
by Therapeutics Class: Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide and Others.
by Route of Administration: Topical,
Oral and Injectable.
by Acne Type:
by Distribution Channels: Speciality Clinics, Retail Pharmacy, Online Pharmacy and Others.
by Geography:
North America (the US, Canada and Mexico), Europe (Germany, the UK,
France, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China,
Japan India, South Korea, Australia and New Zealand and Rest of Asia-Pacific),
South America (Brazil, Argentina, Chile, Colombia and the Rest of South America)
and the Rest of the World (the Middle East and Africa).
Key Takeaways
- Geographically, North America held a dominant market share in 2021, owing to the increasing demand and easy availability of products such as antiacne creams driving the Prescription Antiacne Drugs Market Size.
- The Prescription Antiacne Drugs Market is predicted to be the change in lifestyle and high spending capacity of youths.
- However, the potential side effects may limit the Prescription Antiacne Drugs Industry growth over the forecast period 2022-2027.
- A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Prescription Antiacne Drugs Market Report.
Prescription Antiacne Drugs Market Segment Analysis - by Therapeutic Class
Prescription Antiacne Drugs Market based on the applications can be further segmented into Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide and others. The Retinoids segment held a dominant market share in 2021. It is used as the first line of treatment for acne. Also, retinoids are effective in treating moderate to severe acne, reducing post-inflammatory hyperpigmentation and preventing the formation of new acne. Such properties of retinoids drive the growth of the Prescription Antiacne Drugs Market share. However, Salicylic acid is estimated to grow with the fastest CAGR of 6.3% over the forecast period 2022-2027. It helps the skin to shed dead cells and decreases redness and inflammation. Owing to its exfoliating and antiseptic properties, it is used in various cosmetics products, which are used to treat acne. Such properties of salicylic acids and their increasing use in cosmetics products drive the growth of the Prescription Antiacne Drugs Market share over the forecast period 2022-2027.
Prescription Antiacne Drugs Market Segment Analysis - by Acne Type
Prescription Antiacne Drugs Market based on the acne type can be
further segmented into Non-inflammatory Acne and Inflammatory Acne. The Inflammatory
acne segment held a dominant market share in 2021 and is estimated to grow with the fastest CAGR of 6.1% over
the forecast period 2022-2027. Acne vulgaris is a primary
inflammatory disease and affects 90% of males and 80% of females in all ethnic
groups. As per the health data organization, globally, acne vulgaris is
responsible for 4.96 million Disability Adjusted Life Years (DALYs). Such a high
prevalence of inflammatory acne vulgaris fuels the growth of the Prescription
Antiacne Drugs Market Share over the forecast period 2022-2027.
Prescription Antiacne Drugs Market Segment Analysis - by Geography
North America held a dominant market share of 32% in the year 2021. This is owing to the high prevalence of acne vulgaris in this region. As per the American Association of Dermatology, in 2021, more than 50 million people in the United States suffer from acne. With such a high prevalence of acne, the demand for the antiacne cream industry in the U.S. surged, resulting in the growth of the Prescription Antiacne Drugs Market Size. Furthermore, Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. As per a Regional overview by the United Nations, about 60% of youths live in the Asia-Pacific region. This increases demand for skincare products and fuels the Prescription Antiacne Drugs Market Size over the forecast period 2022-2027.
Prescription Antiacne Drugs Market Drivers
Growing Clinical Approvals for Drugs:
The rising prevalence of acne in teenagers and adults increases the demand for acne treatment. Owing to increasing demand, manufacturers focus on new product launches in the market. For instance, in November 2021, Sun Pharmaceutical Industries announced the availability of WINLEVI cream 1% in the United States, a first-in-class topical androgen receptor inhibitor, approved by the FDA in august 2020. Such new innovative drugs are launched to drive the growth of the Prescription Antiacne Drugs Market over the forecast period 2022-2027.
Growing Occurrence of Acne:
The changes in lifestyle and changing environmental
conditions affect the skin very badly which increases the chances of acne. Acne
can occur at any stage of life and may continue into one’s 30s and 40s. Approximately
85% of people between the ages of 12-24 experience at least minor acne. As per
data published in the British Journal of Dermatology From 1990 to 2019, the
global number of incident acne vulgaris cases increased from 79.7 to 117.4
million. Such a high prevalence of acne increases the demand for antiacne creams and
fuels the growth of the Prescription Antiacne Drugs Market over the forecast
period 2022-2027.
Prescription Antiacne Drugs Market Challenge
Chances of Side Effects:
The treatment of Antiacne Drugs sometimes shows side effects like
dry peeling skin, dizziness, increased sensitivity to the skin and other
potential side effects. Isotretinoin is a treatment for severe acne that comes
in capsules. Cheilitis or dry lips are the most common dose-dependent adverse
effect seen in about 90% of patients taking isotretinoin. Women taking
co-cyprindiol may develop breast cancer in later life. For instance, 16 out of
10,000 have a chance to get breast cancer. Such side effects of the Prescription Antiacne Drugs may limit the growth of the Prescription Antiacne Drugs Industry
over the forecast period 2022-2027.
Prescription Antiacne Drugs Industry Outlook
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Prescription
Antiacne Drugs Market. The top 10 companies in the Prescription Antiacne Drugs
Market are:
- Almirall SA
- Bausch Health Companies Inc.
- Glaxosmithkline plc. (GSK)
- Johnson & Johnson
- Galderma S.A.
- Mayne Pharma Group Limited
- Mylan N.V.
- Sun Pharmaceutical Industries Limited
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Recent Developments
- In August 2022, GSK announced the completion of the acquisition of Affinivax, Inc, a clinical-stage biopharmaceutical company based in Cambridge. The acquisition of Affinivax aligns with GSK’s strategy of building a strong portfolio of specialty medicines and vaccines.
- In March 2022, Bausch Health Companies Inc.'s joint venture, Bausch + Lomb and Clearside Biomedical, announced the U.S. commercial launch of XIPERE (triamcinolone acetonide injectable suspension). This is the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation.
- In July 2021, Almirall S.A., a global biopharmaceutical company focused on skin health, launched its 6th call for proposals with the aim of establishing collaborations in dermatological research to find innovative therapies for skin diseases.
Relevant Titles
Report Code: AGR 0108
Report Code: HCR 47497
Report Code: HCR 1433